









Markets
/
Stocks
/
nasdaq-adag
/

Adagene Inc

ADAG

View Detailed Chart

1.920USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

113.06MMarket Cap

--P/E TTM



Adagene Inc

1.920

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-3.52%

5 Days

-3.52%

1 Month

+3.78%

6 Months

+0.52%

Year to Date

-3.52%

1 Year

-29.67%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

10.857

Target Price

465.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Adagene Inc

ADAG

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(6)

Neutral(2)

Buy(5)

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.012

Buy

RSI(14)

49.998

Neutral

STOCH(KDJ)(9,3,3)

44.239

Sell

ATR(14)

0.168

Low Volatility

CCI(14)

17.950

Neutral

Williams %R

43.860

Buy

TRIX(12,20)

0.152

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.980

Sell

MA10

1.961

Sell

MA20

1.916

Buy

MA50

1.911

Buy

MA100

1.770

Buy

MA200

1.974

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Ticker SymbolADAG

CompanyAdagene Inc

CEODr. Peter (Peizhi) Luo, Ph.D.

Websitehttps://www.adagene.com/